Newcells Head to Boston

International Trade Mission  December 2018 

Newcells Biotech CEO, Dr Mike Nicholds, and CSO, Prof Lyle Armstrong, are delighted to be taking part in a global trade mission hosted by the Department for International Trade and partially funded by the Northern Powerhouse. Dr Nicholds and Prof Armstrong will travel to Greater Boston, which is the home to almost 1,000 drug discovery biotechnology companies, ranging from small start-ups to billion-dollar pharmaceutical companies, all looking to bring new innovative products to market.   

During the trade mission, they will be connecting with representatives from pharmaceutical and biotech companies interested in in-vitro assays for pre-clinical testing of new drugs or collaborating with Newcells on new assay developments. The pair will also be looking to meet with potential US-based partners to expand Newcells Biotech’s reach in North America.  

The mission will focus on the many opportunities Boston has to offer, while taking a closer look at: 

  • Boston’s thriving information technology, education, life sciences, energy and research & development mega-hub 
  • Industry and innovation leaders 
  • Investment opportunities and strategic partnerships

If you are interested in the work Newcells Biotech does and want to arrange a meeting prior to the trade mission,
please contact us on 0333 344 6291.  


You might also be interested in…

Development of functioning in vitro lung assay for modelling Covid-19 infection

Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform for modelling SARS-CoV-2 infection and replication.  Their work alongside the Liverpool School of Tropical Medicine (LTSM) Centre for Drugs and Diagnostics will be crucial in helping

The Biosphere

Newcells Biotech scales up its operations in The Biosphere

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.    The purpose-built space in the city centre site

COVID-19 Vaccine

An Overview of Vaccine Development & Sub-Types

Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have declined for a multitude of diseases, such as Diphtheria, Whooping Cough and Measles.1 However, despite the success of these global vaccination